Our Company
Our Purpose
Partnerships and Community
Toward Health Equity for Black People Impacted by TNBC
Science & Medicine
News and Press
Company Statements
Gilead Statement on Favorable Verdict in HIV PrEP Patents Litigation
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts
Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income Countries
Christi Shaw to Depart Gilead and Kite Leadership End of Q1
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S.
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products
Gilead to Expand Footprint in Oceanside
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD
Gilead Sciences Statement on Recent Events in Washington, D.C.